1.04
4.00%
0.04
Sonnet Biotherapeutics Holdings Inc (SONN) 最新ニュース
Sonnet BioTherapeutics Completes Enrollment in Phase 1 - GlobeNewswire
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors - StockTitan
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics shareholders approve key proposals - Investing.com
Sonnet BioTherapeutics shareholders approve key proposals By Investing.com - Investing.com Canada
Sonnet BioTherapeutics to Present at Investor Series - TipRanks
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - ForexTV.com
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - StockTitan
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
Sonnet BioTherapeutics gets extension to meet Nasdaq rule - Investing.com
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Update - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Given “Buy” Rating at Chardan Capital - Defense World
Holdings of Sonnet BioTherapeutics Holdings Inc (SONN) are aligned with the stars - SETE News
Are Sonnet BioTherapeutics Holdings Inc’shares a good deal? - US Post News
Daily Progress: Sonnet BioTherapeutics Holdings Inc (SONN) Drop -18.83, Closing at 0.66 - The Dwinnex
Sonnet BioTherapeutics advances pancreatic cancer treatment - Investing.com
Sonnet BioTherapeutics Enters into Clinical Collaboration - GlobeNewswire
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer - Yahoo Finance
why Sonnet BioTherapeutics Holdings Inc [SONN] is a Good Choice for Investors After New Price Target of $14.67 - The DBT News
Company’s Banking Shares: Up -91.97% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Sonnet BioTherapeutics (NASDAQ:SONN) Announces Earnings Results - Defense World
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - StockTitan
SONN stock touches 52-week low at $0.71 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 168.1% in July - Defense World
SONN stock touches 52-week low at $0.71 amid market challenges - Investing.com
SONN stock touches 52-week low at $0.76 amid market challenges - Investing.com
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Can you still get a good price for Sonnet BioTherapeutics Holdings Inc (SONN) Shares at this point? - US Post News
Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - Yahoo Finance
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study - ForexTV.com
Sonnet BioTherapeutics Reports Encouraging Data from Phase - GlobeNewswire
Sonnet BioTherapeutics (NASDAQ:SONN) Shares Down 1.1% - Defense World
Sonnet BioTherapeutics files to sell 5.77M shares of common stock for holders (SONN) - Seeking Alpha
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session - Quantisnow
Sonnet BioTherapeutics announces exercise of warrants for $3.4M in proceeds - TipRanks
Sonnet BioTherapeutics announces exercise of warrants for $3.4M in proceedsTipRanks.com - TipRanks
SONNSonnet BioTherapeutics Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Sonnet BioTherapeutics sets terms for warrant exercise By Investing.com - Investing.com
Willamette Valley Vineyards CEO acquires $9.8k in company stock By Investing.com - Investing.com
Sonnet BioTherapeutics sets terms for warrant exercise - Investing.com India
Sonnet BioTherapeutics sets terms for warrant exercise By Investing.com - Investing.com UK
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds - GlobeNewswire
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds - StockTitan
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds - Yahoo Finance
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Sees Large Drop in Short Interest - Defense World
Sonnet Biotherapeutics announces new immunotherapeutic compounds - BioWorld Online
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline ... - GlobeNewswire
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline ... - StockTitan
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain - GlobeNewswire
Sonnet BioTherapeutics (NASDAQ:SONN) versus Salarius Pharmaceuticals (NASDAQ:SLRX) Critical Survey - Defense World
Research Analysts Set Expectations for Sonnet BioTherapeutics Holdings, Inc.'s FY2024 Earnings (NASDAQ:SONN) - Defense World
Trading Day Review: Sonnet BioTherapeutics Holdings Inc (SONN) Gains Momentum, Closing at 1.65 – DWinneX - The Dwinnex
Sonnet BioTherapeutics' (SONN) Buy Rating Reaffirmed at Chardan Capital - Defense World
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting - GlobeNewswire
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting - Yahoo Canada Finance
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting - Yahoo Finance Australia
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference - The Globe and Mail
Sonnet BioTherapeutics announces review of strategic alternativesTipRanks.com - TipRanks
Sonnet BioTherapeutics Announces Review of Strategic Alternatives - Miami Herald
Sonnet BioTherapeutics Announces Review of Strategic Alternatives - Yahoo Finance
Sonnet BioTherapeutics announces updated clinical data for SON-1010TipRanks.com - TipRanks
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti ... - WDRB
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti ... - Yahoo Finance
大文字化:
|
ボリューム (24 時間):